ML239

ML239 (CID-49843203) 是乳腺癌肿瘤干细胞的选择性抑制剂(C50:1.16 μM)。

产品编号 T4399Cas号 1378872-36-6

选择批次:

纯度:99.82%

联系我们获取更多批次信息

资源下载

产品编号 T4399别名 CID-49843203Cas号 1378872-36-6

ML239 (CID-49843203) 是乳腺癌肿瘤干细胞的选择性抑制剂(C50:1.16 μM)。

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

大包装 & 定制

加入购物车

实验操作小课堂

生物活性

产品描述	ML239 (CID-49843203) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
靶点活性	Breast cancer stem cells:1.16 μM.
体外活性	ML239是一种针对乳腺癌干细胞的有效且选择性的抑制剂，其IC50为1.16 µM。ML239通过激活脂肪酸脱氢酶2（FADS2）的途径，抑制乳腺癌类干细胞。ML239对NCIH661细胞具有细胞毒性，FADS2的敲除降低了ML239的细胞毒性，此外，FADS2抑制剂SC-26196也降低了在癌细胞系（CCLs）中ML239的细胞毒性。
激酶实验	ML239 is dissolved in DMSO.Cancer cell lines (CCLs) are plated at a density of 500 cells/well in white opaque tissue-culture-treated Aurora 1536-well MaKO plates in the provider-recommended growth media using a highly automated platform. Compounds (ML239) are added by acoustic transfer using a Labcyte Echo 555. 24 hours after plating. The effects of small molecules (ML239) are measured over a 16-point concentration range (two-fold dilution) in duplicate. DMSO is used at a constant concentration of 0.33%, including vehicle-only control wells. As a surrogate for viability, cellular ATP levels are assessed 72 hours after compound transfer by addition of CellTiterGlo followed by luminescence measurement using a ViewLux Microplate Imager. Duplicates are averaged and luminescence values normalized to vehicle (DMSO) treatment and background (media-only) wells
别名	CID-49843203

化学信息

储存&溶解度

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

溶解度信息

DMSO: 50 mg/mL (144.26 mM)

Ethanol: 50 mM

溶液配制表

Ethanol/DMSO